TY - JOUR
T1 - Characterization of drug-resistant cell lines by comparative genomic hybridization
AU - Carlson, Katrin M.
AU - Gruber, Astrid
AU - Liliemark, Eva
AU - Larsson, Rolf
AU - Nordenskjöld, Magnus
PY - 1999/5/1
Y1 - 1999/5/1
N2 - The development of resistance to cytostatic agents is a serious obstacle to the success of cancer therapy and has been the focus of many research efforts. Traditionally, cell lines are selectively cultured in the presence of cytostatic agents and the biochemical and cytogenetic properties of the cell lines are then analyzed. In order to better understand the mechanisms by which drug resistance is mediated, we have analyzed three cell lines, each derived from the parent line K562, which are resistant to vincristine, mitoxantrone, or idarubicin, using comparative genomic hybridization (CGH). In each case, CGH successfully identified amplifications and/or deletions unique to the drug-resistant selected cell lines. Further characterization of the genetic regions identified in the CGH analysis could greatly contribute to our understanding of acquired drug resistance, and could potentially impact the clinical management of cancer.
AB - The development of resistance to cytostatic agents is a serious obstacle to the success of cancer therapy and has been the focus of many research efforts. Traditionally, cell lines are selectively cultured in the presence of cytostatic agents and the biochemical and cytogenetic properties of the cell lines are then analyzed. In order to better understand the mechanisms by which drug resistance is mediated, we have analyzed three cell lines, each derived from the parent line K562, which are resistant to vincristine, mitoxantrone, or idarubicin, using comparative genomic hybridization (CGH). In each case, CGH successfully identified amplifications and/or deletions unique to the drug-resistant selected cell lines. Further characterization of the genetic regions identified in the CGH analysis could greatly contribute to our understanding of acquired drug resistance, and could potentially impact the clinical management of cancer.
UR - http://www.scopus.com/inward/record.url?scp=0032958978&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0032958978&partnerID=8YFLogxK
U2 - 10.1016/S0165-4608(98)00222-2
DO - 10.1016/S0165-4608(98)00222-2
M3 - Article
C2 - 10326588
AN - SCOPUS:0032958978
VL - 111
SP - 32
EP - 36
JO - Cancer Genetics and Cytogenetics
JF - Cancer Genetics and Cytogenetics
SN - 0165-4608
IS - 1
ER -